LongRiver Investments

About LongRiver Investments

LongRiver Investments is a venture capital firm with dual presence in Hong Kong (Unit 1551, 15/F, AIA Central) and Cambridge, United Kingdom, with the UK office opened in early 2025 covering the Cambridge-Oxford-London corridor. The firm was founded in 2022 by a former CEO of Ping An Ventures. Assets under management as of December 2024 stand at USD 385 million (approximately €355 million) following the debut fund close in July 2024. The structure is a USD-denominated venture capital partnership. The firm is a BVCA member with the UK office as a strategic European launchpad. There is one disclosed fund vehicle (LongRiver USD Fund I, USD 385 million 2024 vintage). The Cambridge office is led by Dr. Jerry Wu, Managing Director and Head of UK Office, formerly Head of Investment at TusPark Holdings UK.

Investment thesis

LongRiver Investments pursues an early-stage venture capital strategy from angel rounds through Series B, with the firm leading several Series A rounds. The firm describes managing the full investment cycle from sourcing to exit with 10-plus years of cumulative healthcare and deep tech experience in the founding team. Sector focus is healthcare (biotech, interdisciplinary medical technologies, materials science applied to pharmaceuticals and consumer healthcare) and deep tech. The UK office specifically targets biotech and deep tech in the Cambridge-Oxford-London corridor. Geographic scope is global with primary concentration in China, the United States and Europe (UK-led for European deployment). Ticket size is USD 5 to 10 million per investment. The limited partner base includes leading European and Asian insurance companies, asset management firms and funds-of-funds. Value creation operates through operational support drawing on cross-border China-US-Europe commercialisation networks, with the Cambridge office sourcing biotech and life-science deals at the academic-to-commercial interface.

Recent activity

Recent investments include Rona Therapeutics in biotech (2024 led USD 35 million Series A-plus in July 2024), Axoft in biotech and medical devices covering soft neural interfaces, Oculgen in biotech covering ophthalmic therapeutics, and Ronovo Surgical in medical devices covering robotic and telesurgery. Recent exits include Ouro Medicines in biotech (March 2026, Fund I realised exit). The platform continues active deployment of Fund I across healthcare biotech and deep tech in the Cambridge-Oxford-London corridor and global cross-border opportunities. The UK office leverages the broader Cambridge research ecosystem ties spanning Wellcome Sanger, EMBL-EBI and Cambridge Institute for Medical Research. Detailed buyer names and multiple data available on Pro at €29/month.